Molecular Partners (NASDAQ:MOLN – Get Free Report) and Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.
Institutional and Insider Ownership
26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are held by institutional investors. 5.9% of Molecular Partners shares are held by insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and price targets for Molecular Partners and Cartesian Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Molecular Partners | 1 | 1 | 2 | 0 | 2.25 |
| Cartesian Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
Molecular Partners presently has a consensus target price of $8.38, suggesting a potential upside of 162.62%. Cartesian Therapeutics has a consensus target price of $32.60, suggesting a potential upside of 408.58%. Given Cartesian Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Cartesian Therapeutics is more favorable than Molecular Partners.
Profitability
This table compares Molecular Partners and Cartesian Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Molecular Partners | N/A | -80.03% | -62.56% |
| Cartesian Therapeutics | -8,550.65% | N/A | -29.84% |
Risk and Volatility
Molecular Partners has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.
Valuation and Earnings
This table compares Molecular Partners and Cartesian Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Molecular Partners | $5.65 million | 22.79 | -$74.41 million | ($1.68) | -1.90 |
| Cartesian Therapeutics | $2.80 million | 69.25 | -$130.30 million | ($5.94) | -1.08 |
Molecular Partners has higher revenue and earnings than Cartesian Therapeutics. Molecular Partners is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Cartesian Therapeutics beats Molecular Partners on 8 of the 13 factors compared between the two stocks.
About Molecular Partners
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
